Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06558708
PHASE2

A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection OD

Sponsor: Gan and Lee Pharmaceuticals, USA

View on ClinicalTrials.gov

Summary

This trial is conducted in China. The aim of the trial is to compare the efficacy, tolerability, and safety of GZR101 Injection and GZR33-70 Injection in type 2 diabetes inadequately controlled on basal/ premixed insulin once daily at least with or without pre-dinner meal-time insulin.

Official title: A Phase II Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection and GZR33-70 Injection in Type 2 Diabetes Inadequately Controlled on Basal Insulin or Premixed Insulin Once Daily at Least With or Without Pre-dinner Meal-time Insulin

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2024-06-28

Completion Date

2024-12

Last Updated

2024-08-19

Healthy Volunteers

No

Conditions

Interventions

DRUG

GZR101 Injection

Once daily

DRUG

GZR33 Injection

Once daily

DRUG

Insulin aspart

Once daily

Locations (1)

Study Site 01

Tianjin, China